CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

EMA begins review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA: Amsterdam, The Netherlands Monday, February 2, 2026, 14:00 Hrs [IST] European Medicines Agencys ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare ...

"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits and risks of Tavneos," said the EU regulator. "The agency will then issue a ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a review of Amgen’s Tavneos (avacopan), ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their ...

The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV. Prophylactic use of ...

Please provide your email address to receive an email when new articles are posted on . New Pan American League of Associations for Rheumatology recommendations include remission maintenance ...

Higher relapse rates were associated with c-ANCA/PR3 positivity and granulomatosis with polyangiitis phenotype. In a retrospective study of patients with antineutrophil cytoplasmic (ANCA)-associated ...

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic ...